To characterize the antitumor immune response in murine EO771 breast cancer induced by the two doses of intratumoral IL-15 complexes, we collected tumors at day twelve across treatment groups (two days following the second dose in groups receiving IL-15 complex treatment). This evidence concerns the gene IL15 and breast carcinoma.